Display Settings:

Format

Send to:

Choose Destination
Accession: PRJNA471534 ID: 471534

KDM5 inhibition is a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas [1] (human)

See Genome Information for Homo sapiens
Loss of function mutations within KMT2D are a striking feature of the germinal centre lymphomas, with lesions present in 80% of Follicular Lymphoma (FL) and 30% of Diffuse Large B-cell Lymphoma (DLBCL), resulting in decreased H3K4 methylation and altered gene expression. More...
AccessionPRJNA471534; GEO: GSE114492
ScopeMultiisolate
OrganismHomo sapiens[Taxonomy ID: 9606]
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo; Homo sapiens
PublicationsHeward J et al., "KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.", Blood, 2021 Aug 5;138(5):370-381
SubmissionRegistration date: 15-May-2018
Barts Cancer Institute
RelevanceMedical
Project Data:
Resource NameNumber
of Links
Sequence data
SRA Experiments58
Publications
PubMed1
PMC1
Other datasets
BioSample58
GEO DataSets1
GEO Data Details
ParameterValue
Data volume, Supplementary Mbytes2647
SRA Data Details
ParameterValue
Data volume, Gbases339
Data volume, Tbytes0.18

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center